Recession not affecting Indian CRO business

The indian Clinical Research Industry is about $200 million and expected to touch the target of $600 million by 2010. Recession is proving to be boon for the Indian pharma sector with many MNCs like AstraZeneca and Glaxo increasing their outsourcing in clinical trails and also manufacturing of drugs.

By outsourcing clinical trials to India, MNCs can save 50-70% of total cost involved in the process.

Fisher BioPharma, a US MNC planning an additional facility in Gujrat.
Novartis is going to add another 100 jobs at their Hyderabad facilty, where data management services are executed.

Oncology Services Europe (OSE), a CRO specializing in oncology, has launched its India operations at Ahmedabad setting up clinical services company Oncology Services India (OSI).